Clinical Trials Logo

Filter by:
NCT ID: NCT01734863 Withdrawn - Ewing's Sarcoma Clinical Trials

Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients

Start date: September 2012
Phase: Phase 3
Study type: Interventional

Local recurrence after surgical resection is a complex phenomenon. An important predictive factor is the response to chemotherapy. Central site of disease may be a second independent predictive factor (Lin et al. 2007). Patients with more than 10% viable tumour cells at surgery following neo-adjuvant chemotherapy had a less favourable outcome with an Event-free Survival [EFS] of 47% after 10 years. Patients with good histological response (< 10% viable tumour cells) after chemotherapy alone had a prognosis of about 70% after 10 years. However, further studies are necessary to determine the merit of adjuvant radiation for high-risk patients (poor responders). Taking into consideration that the toxicity and morbidity of combined surgery and radiation is greater than either alone and must be closely monitored.

NCT ID: NCT01718340 Withdrawn - Abortion, Habitual Clinical Trials

Effectiveness of Metformin in Recurrent Miscarriage in a Woman With Hyperinsulinaemia

MetRPL
Start date: June 2012
Phase: Phase 4
Study type: Interventional

The prevalence of insulin resistance is increased in women with recurrent miscarriage compared with matched fertile controls,Insulin resistance (IR) in this syndrome is not only implicated toward early pregnancy loss (EPL) but also pathognomic for various obstetrical complications during pregnancy.An elevated free androgen index appears to be a prognostic factor for a subsequent miscarriage in women with recurrent miscarriage. There is insufficient evidence to evaluate the effect of metformin supplementation in pregnancy to prevent a miscarriage in women with recurrent miscarriage.

NCT ID: NCT01679691 Withdrawn - Bone Tumor Clinical Trials

The Epidural Anesthesia on the Intra-operative and Post-operative Amount of Bleeding Post Lower Limb Salvage Surgery

Start date: September 2011
Phase: N/A
Study type: Interventional

Epidural anesthesia is a very useful tool in lower limb salvage surgery, which helps pain control intra and more importantly post-operative pain. It is a well-known effect of epidural injections to cause a sympathetic stimulation and consequently vasodilatation in the lower limb vessels. Since epidural catheters can cause vasodilatation in lower limb vessels, they can subsequently lead to increased intra and post-operative bleeding from the surgical wound. The study will involve all patients having a bone tumor in the lower limb and subjected to tumor resection and reconstruction by prosthesis. The patient will be randomized according to the administration of epidural anesthesia into two arms, an arm in which epidural anesthesia was employed and another arm in which the patient was subjected only to general anesthesia and the amount of intra and postoperative bleeding will be compared in both arms.

NCT ID: NCT01679561 Withdrawn - Clinical trials for Pregnancy Complicated by Low Implantation

Intralipid Therapy for Recurrent Implantation Failure and Recurrent Miscarriages: Is it a Hope or Myth?A Randomized Clinical Trial

ILRIFRM
Start date: February 2012
Phase: Phase 4
Study type: Interventional

Both organ-specific and systemic autoimmunity are associated with an increased prevalence of recurrent miscarriage and reproductive failure, rendering the role of the maternal immunological system in fertility a key concept. It is believed by some that central to this theme is the maternal cytokine profile, with particularly T-helper (Th) cells. Immune modulating therapies have therefore been mooted as potential therapeutic strategies. Recent reports of high pregnancy rates achievable in women with RIF have added fuel to the debate regarding the effectiveness of intralipids in modulating the immune system.

NCT ID: NCT01607866 Withdrawn - Clinical trials for Pleomorphic Adenoma of the Parotid Gland

Quadrant Versus Superficial Parotidectomy

Start date: June 2014
Phase: Phase 2/Phase 3
Study type: Interventional

The most common benign tumor of the parotid gland is the so called pleomorphic adenoma. Although benign, this tumor may recur after surgical removal due to tumor cells left behind during the surgical operation. Thus, pleomorphic adenomas have been treated with wide resection similar to malignant tumors. This extensive surgery often leads to injury to the motor nerves responsible for facial expression and eye protection. The investigators propose less extensive surgery which should be thorough enough to prevent tumor recurrence while keeping the facial nerve out of risk.

NCT ID: NCT01536327 Withdrawn - Muscle Weakness Clinical Trials

Biomarker for Metachromatic Leukodystrophy (BioMeta) Disease

BioMeta
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the early and sensitive diagnosis of Metachromatic Leu-kodystrophy disease from blood (plasma)

NCT ID: NCT01458613 Withdrawn - Lung Diseases Clinical Trials

Biomarker for Maroteaux-Lamy Disease (BioMaroteaux)

BioMaroteaux
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the early and sensitive diagnosis of Maroteaux-Lamy disease from blood

NCT ID: NCT01457456 Withdrawn - Morquio B Disease Clinical Trials

Biomarker for Morquio Disease (BioMorquio)

BioMorquio
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the early and sensitive diagnosis of Morquio disease from plasma

NCT ID: NCT01447394 Withdrawn - Clinical trials for Hepatitis C Virus (HCV)

Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C

Start date: March 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if 48 weeks of therapy with Pegylated Interferon Lambda plus Ribavirin is effective and safe for a treatment of chronic hepatitis C (CHC) compared to therapy with Pegylated Interferon Alfa-2a plus Ribavirin.

NCT ID: NCT01425489 Withdrawn - Krabbe Disease Clinical Trials

Biomarker for Krabbe Disease (BioKrabbe)

BIOKRABBE
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the early and sensitive diagnosis of Krabbe Disease from blood